Difference between revisions of "Team:ASIJ Tokyo"
19andersonn (Talk | contribs) |
|||
| Line 2: | Line 2: | ||
<html> | <html> | ||
<style> | <style> | ||
| + | |||
body { | body { | ||
margin-left: 10px; | margin-left: 10px; | ||
margin-right: 10px; | margin-right: 10px; | ||
} | } | ||
| + | |||
#everything { | #everything { | ||
| − | background-color: # | + | background-color: #fddea5 |
| + | } | ||
| + | |||
| + | #banner { | ||
| + | position: relative; | ||
| + | left: 100px; | ||
| + | top: 0px; | ||
| + | width: 1000px; | ||
} | } | ||
#liver { | #liver { | ||
| − | position: | + | position: relative; |
| − | left: | + | left: -850px; |
| − | top: | + | top: 0px; |
width: 500px; | width: 500px; | ||
} | } | ||
| + | |||
#title p{ | #title p{ | ||
font-size: 85px; | font-size: 85px; | ||
| Line 27: | Line 37: | ||
letter-spacing: 15px; | letter-spacing: 15px; | ||
} | } | ||
| + | |||
#red { | #red { | ||
color: #c53d43; | color: #c53d43; | ||
} | } | ||
| + | |||
div.container | div.container | ||
{ | { | ||
| Line 40: | Line 52: | ||
text-align: center; | text-align: center; | ||
} | } | ||
| + | |||
div.container a | div.container a | ||
{ | { | ||
| − | color: # | + | color: #FFF; |
text-decoration: none; | text-decoration: none; | ||
font: 20px Avenir; | font: 20px Avenir; | ||
| − | |||
margin: 0px 10px; | margin: 0px 10px; | ||
padding: 10px 10px; | padding: 10px 10px; | ||
| Line 52: | Line 64: | ||
cursor: pointer; | cursor: pointer; | ||
} | } | ||
| + | |||
div.topBotomBordersOut a:before, div.topBotomBordersOut a:after | div.topBotomBordersOut a:before, div.topBotomBordersOut a:after | ||
{ | { | ||
| Line 58: | Line 71: | ||
width: 100%; | width: 100%; | ||
height: 2px; | height: 2px; | ||
| − | background: # | + | background: #FFF; |
content: ""; | content: ""; | ||
opacity: 0; | opacity: 0; | ||
| Line 65: | Line 78: | ||
div.topBotomBordersOut a:before | div.topBotomBordersOut a:before | ||
{ | { | ||
| − | top: | + | top: 10px; |
transform: translateY(10px); | transform: translateY(10px); | ||
} | } | ||
div.topBotomBordersOut a:after | div.topBotomBordersOut a:after | ||
{ | { | ||
| − | bottom: | + | bottom: 10px; |
transform: translateY(-10px); | transform: translateY(-10px); | ||
} | } | ||
| Line 82: | Line 95: | ||
top: 500px; | top: 500px; | ||
} | } | ||
| + | |||
</style> | </style> | ||
| Line 92: | Line 106: | ||
<body> | <body> | ||
<div id="everything"> | <div id="everything"> | ||
| + | <div id="banner"><img src="https://static.igem.org/mediawiki/2018/2/2d/T--ASIJ_Tokyo--teambanner.png" id="banner"></img></div> | ||
<div class="container topBotomBordersOut"> | <div class="container topBotomBordersOut"> | ||
<a href="#">HOME</a> | <a href="#">HOME</a> | ||
| Line 100: | Line 115: | ||
<a href="https://2018.igem.org/Team:ASIJ_Tokyo/Safety">SAFETY</a> | <a href="https://2018.igem.org/Team:ASIJ_Tokyo/Safety">SAFETY</a> | ||
</div> | </div> | ||
| − | |||
<div id="title"><p>A1-AT<br>DE<span id="red">LIVER</span>Y </p></div> | <div id="title"><p>A1-AT<br>DE<span id="red">LIVER</span>Y </p></div> | ||
| − | <img src="https://static.igem.org/mediawiki/2018/e/ed/T--ASIJ_Tokyo--liverlogocut.png" id="liver"></img> | + | <img src="https://static.igem.org/mediawiki/2018/e/ed/T--ASIJ_Tokyo--liverlogocut.png" align="right" id="liver"></img> |
<div id="abstract"> | <div id="abstract"> | ||
<h1> A1AT deLIVERy - Using Stem Cell and CRISPR Technology to Combat Alpha-1 Antitrypsin Deficiency </h1> | <h1> A1AT deLIVERy - Using Stem Cell and CRISPR Technology to Combat Alpha-1 Antitrypsin Deficiency </h1> | ||
Revision as of 04:43, 29 June 2018
A1-AT
DELIVERY
A1AT deLIVERy - Using Stem Cell and CRISPR Technology to Combat Alpha-1 Antitrypsin Deficiency
ABSTRACT
Alpha-1 Antitrypsin deficiency is a common genetic disorder -- the defective gene for which is carried by 1 in 25 people -- which arises from a single base pair mutation in the SERPINA1 gene, resulting in the production of a form of antitrypsin prone to polymerization. The mutated antitrypsin then builds up in liver cells and is unable to inhibit proteases in the lungs, leading to damage in both. Using CRISPR-Cas9 technology, we aimed to fix the error in SERPINA1 so that proper antitrypsin can be produced. We will show proof of concept in E. Coli cells using osmy secretion tags and GFP as a reporter. We hope to design a liver organ bud using IPS cell technology to deliver function A1AT through collaboration with Dr. Kagimoto of Healios Japan KK.